Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hodgkin/Reed-Sternberg cells induce GPNMB expression and release from macrophages to suppress T-cell responses to the Epstein-Barr virus-encoded LMP2A protein.
Masand N, Perry TA, Pugh M, Fennell E, Hennessy A, Wei W, Bouchalova K, Burns D, Kearns P, Taylor G, Vrzalikova K, Murray PG. Masand N, et al. Among authors: kearns p. Haematologica. 2024 Aug 22. doi: 10.3324/haematol.2024.285319. Online ahead of print. Haematologica. 2024. PMID: 39219456 Free article.
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.
Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I, Lindsey BB, Kearns P, Barnes E, Goodyear CS, Richter A, Thomas D, Cook G, McInnes IB, Willicombe M, Siebert S, Orchard K, Selby R, Bowden S, Collini PJ, Pope A, Kirkham A, Kronsteiner B, Dunachie SJ, Miller P, Clay J, Hurst E, Malladi R, Kesavan M, Kinsella F, Sanderson R, Yong KL, Rea D, Parry H; PITCH Consortium, OCTAVE Collaborative Group, OCTAVE‐DUO Investigators, PROSECO Investigators; Lim SH, Snowden JA, de Silva TI. Colton H, et al. Among authors: kearns p. Br J Haematol. 2024 Nov 17. doi: 10.1111/bjh.19874. Online ahead of print. Br J Haematol. 2024. PMID: 39551718
Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998.
Chisholm J, Mandeville H, Adams M, Minard-Collin V, Rogers T, Kelsey A, Shipley J, van Rijn RR, de Vries I, van Ewijk R, de Keizer B, Gatz SA, Casanova M, Hjalgrim LL, Firth C, Wheatley K, Kearns P, Liu W, Kirkham A, Rees H, Bisogno G, Wasti A, Wakeling S, Heenen D, Tweddle DA, Merks JHM, Jenney M. Chisholm J, et al. Among authors: kearns p. Cancers (Basel). 2024 Oct 9;16(19):3427. doi: 10.3390/cancers16193427. Cancers (Basel). 2024. PMID: 39410054 Free PMC article.
Fatigue in early multiple sclerosis: MRI metrics of neuroinflammation, relapse and neurodegeneration.
Meijboom R, Foley P, MacDougall NJJ, Mina Y, York EN, Kampaite A, Mollison D, Kearns PKA, White N, Thrippleton MJ, Murray K, Valdés Hernández MDC, Reich DS, Connick P, Jacobson S, Nair G, Chandran S, Waldman AD. Meijboom R, et al. Among authors: kearns pka. Brain Commun. 2024 Aug 14;6(5):fcae278. doi: 10.1093/braincomms/fcae278. eCollection 2024. Brain Commun. 2024. PMID: 39386090 Free PMC article.
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.
Pal S, Chataway J, Swingler R, Macleod MR, Carragher NO, Hardingham G, Selvaraj BT, Smith C, Wong C, Newton J, Lyle D, Stenson A, Dakin RS, Ihenacho A, Colville S, Mehta AR, Stallard N, Carpenter JR, Parker RA, Keerie C, Weir CJ, Virgo B, Morris S, Waters N, Gray B, MacDonald D, MacDonald E, Parmar MKB, Chandran S; MND SMART Investigators. Pal S, et al. Lancet Neurol. 2024 Nov;23(11):1097-1107. doi: 10.1016/S1474-4422(24)00326-0. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307154 Free article. Clinical Trial.
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer.
Bautista F, Verdú-Amorós J, Geoerger B, Rubio-San-Simón A, Paoletti X, Zwaan CM, Casanova M, Marshall LV, Carceller F, Doz F, Lecinse C, Vassal G, Pearson ADJ, Kearns P, Moreno L; Innovative Therapies For Children With Cancer Consortium. Bautista F, et al. Among authors: kearns p. J Clin Oncol. 2024 Jul 20;42(21):2516-2526. doi: 10.1200/JCO.23.01237. Epub 2024 May 14. J Clin Oncol. 2024. PMID: 38743911
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Among authors: kearns p. Lancet Rheumatol. 2024 Jun;6(6):e339-e351. doi: 10.1016/S2665-9913(24)00065-1. Epub 2024 May 8. Lancet Rheumatol. 2024. PMID: 38734019 Free article. Clinical Trial.
311 results